Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility

IDrugs

Volumn 12, Issue 6, 2009, Pages 381-393

  Tiwari, Atul ^a  

^a JUBILANT BIOSYS LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITRIOL; CALCIUM; DOXAZOSIN; DUTASTERIDE; ELOCALCITOL; EPIRUBICIN; FINASTERIDE; INTERLEUKIN 8; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; DRUG DERIVATIVE;

AMNESIA; APOPTOSIS; ASTHENIA; BLADDER CANCER; BLADDER CONTRACTION; CALCIUM URINE LEVEL; CARDIAC GRAFT REJECTION; CELL PROLIFERATION; CLINICAL TRIAL; COGNITIVE DEFECT; CYSTITIS; DIABETES MELLITUS; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EJACULATION DISORDER; FLOPPY IRIS SYNDROME; GYNECOMASTIA; HEADACHE; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; IMPOTENCE; IRIS DISEASE; LIBIDO; MALE INFERTILITY; MONOTHERAPY; NOCTURIA; NONHUMAN; ORGAN WEIGHT; ORTHOSTATIC HYPOTENSION; OSTEOPENIA; OSTEOPOROSIS; OVERACTIVE BLADDER; PROSTATE; PROSTATE HYPERTROPHY; PROSTATITIS; RETROGRADE EJACULATION; REVIEW; RHINITIS; SIDE EFFECT; SOMNOLENCE; SPERM; SPERMATOZOON MOTILITY; STANDING; STRUCTURE ACTIVITY RELATION; SYNCOPE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; ANIMAL; ARTICLE; DRUG EFFECT; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL;

ANIMALS; APOPTOSIS; CALCITRIOL; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; INFERTILITY, MALE; MALE; PROSTATIC HYPERPLASIA; RECEPTORS, CALCITRIOL; URINARY BLADDER, OVERACTIVE;

EID: 67650669008     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. The present role of α-adrenergic blockers in the treatment of benign prostatic hypertrophy. Caine M J UROL 1986 136 1 1-4
2. Investor presentation (Q3 sales). Roche Holding AG COMPANY PRESENTATION 2001 October 16
3. New biotech start-up formed under Roche leadership. Roche Holding AG PRESS RELEASE 2002 March 26
4. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z ENDOCRINOLOGY 2002 143 5 1625-1636
5. 3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L DIABETES 2002 51 5 1367-1374
6. BioXell: Pipeline validation - BXL-628 phase I trials complete. BioXell SpA COMPANY COMMUNICATION 2002 July 25
7. Vitamin D analogs as therapeutic agents: A clinical study update. Wu Wong JR, Tian J, Goltzman D CURR OPIN INVEST DRUGS 2004 5 3 320-326
8. BioXell acquires rights from Roche to develop BXL 628 in additional indications. BioXell SpA PRESS RELEASE 2004 June 28
9. BioXell to commence phase IIa trial of its lead compound, BXL628, in overactive bladder. BioXell SpA PRESS RELEASE 2004 November 29
10. BioXell initiates phase IIa trial of its lead compound BXL628 in chronic non-bacterial prostatitis. BioXell SpA PRESS RELEASE 2005 November 07
11. BioXell announces phase II results for elocalcitol in overactive bladder. BioXell SpA PRESS RELEASE 2006 May 11
12. Vitamin D receptor ligands for osteoporosis. Cheskis BJ, Freedman LP, Nagpal S CURR OPIN INVEST DRUGS 2006 7 10 906-911
13. BioXell: Innovations and medicines. BioXell SpA COMPANY WORLD WIDE WEB SITE 2006 October 12
14. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Sanvito F, Doglioni C, Adorini L J IMMUNOL 2006 177 12 8504-8511
15. Sperm quality and pregnancy rate after COX-2 inhibitor therapy of infertile males with abacterial leukocytospermia. Gambera L, Serafini F, Morgante G, Focarelli R, De Leo V, Piomboni P HUM REPROD 2007 22 4 1047-1051
16. BioXell starts phase IIb European trial of elocalcitol in overactive bladder. BioXell SpA PRESS RELEASE 2007 July 23
17. BioXell announces positive phase IIb results for elocalcitol in benign prostatic hyperplasia. BioXell SpA PRESS RELEASE 2007 October 12
18. BioXell announces start of phase IIa trial of elocalcitol in male infertility. BioXell SpA PRESS RELEASE 2007 November 19
19. Elocalcitol in the treatment of BPH: A multicenter, randomized, placebo-controlled phase IIb clinical trial. Montorsi F, Colli E J UROL 2008 179 4 Suppl Abs 2035
20. Meeting highlights from the Paediatric Committee, 6-8 May 2008. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2008 May 15
21. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. Crescioli C, Borgogni E, Sarchielli E, Sottili M, Santarlasci V, Cosmi L, Gelmini S, Lombardi A, Cantini G, Perigli G, Luconi M et al ENDOCRINOLOGY 2008 149 7 3626-3634
22. BioXell reports highlights and financial results for the first six months of 2008. BioXell SpA PRESS RELEASE 2008 August 12
23. 3 analogue (BXL628) has anti-inflammatory effects in rodent model of interstitial cystitis. Benigni F, Baroni E, Zecevic M, Zvara P, Streng T, Hedlund P, Colli E, D'Ambrosio D, Andersson Karl-Erik BJU INT 2006 97 3 617-624
24. 3 analog arrests prostate growth in patients with benign prostatic hyperplasia: A randomized clinical trial. Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, Scarpa R, Usai P, Olivieri L, Maggi M EUR UROL 2006 49 1 82-86
25. Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Amuchastegui S, Daniel KC, Adorini L TRANSPLANTATION 2005 80 1 81-87
26. Chemical reactivity of Ro-26-9228, 1α-fluoro-25-hydroxy- 16,23E-diene-26,27-bishomo-20-epi-cholecalciferol in aqueous solution. Brandl M, Wu X, Liu Y, Pease J, Holper M, Hooijmaaijer E, Lu Y, Wu Ping J PHARM SCI 2003 92 10 1981-1989
27. Therapeutic effects in postmenopausal, osteoporotic (PMOP) women of a vitamin D analog, Ro-26-9228, with minimal effects on calcium (Ca) homeostasis. Tong SE, Wasnich RD, Harris ST, Weiss SR, Bolognese MA, Cohen SB, Silverman SL, Gallagher JC J BONE MINER RES 2000 15 Suppl 1 S562
28. The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder. Morelli A, Squecco R, Failli P, Filippi S, Vignozzi L, Chavalmane AK, Fibbi B, Mancina R, Luciani G, Gacci M, Colli E et al AM J PHYSIOL - CELL PHYSIOL 2008 294 5 C1206-C1214
29. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, Crescioli C, Donati S, Fibbi B, Colli E, Adorini L et al PROSTATE 2007 67 3 234-247
30. The vitamin D analogue BXL-628 inhibits growth factorstimulated proliferation and invasion of DU145 prostate cancer cells. Marchiani S, Bonaccorsi L, Ferruzzi P, Crescioli C, Muratori M, Adorini L, Forti G, Maggi M, Baldi E J CANCER RES CLIN ONCOL 2006 132 6 408-416
31. Benign prostatic hyperplasia: An insight into current investigational medical therapies. Tiwari A, Krishna NS, Nanda K, Chugh A EXPERT OPIN INVEST DRUGS 2005 14 11 1359-1372
32. Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia. Tiwari A EXPERT OPIN INVEST DRUGS 2007 16 9 1425-1439
33. WO-200843857: Vitamin D compounds-useful for treating sub-fertile men suffering from prostatic disease. Adorini L, Penna G, Colli E WORLD PATENT 2008 April 17
34. 3 on primary cultures of human prostatic cells. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D CANCER RES 1994 54 3 805-810
35. 3 receptors and actions in human prostate cancer cell lines. Skowronski RJ, Peehl DM, Feldman D ENDOCRINOLOGY 1993 132 5 1952-1960
36. Hormonal signaling in prostatic hyperplasia and neoplasia. Marcelli M, Cunningham GR J CLIN ENDOCRINOL METAB 1999 84 10 3463-3468
37. Comorbidities associated with overactive bladder. Brown JS, McGhan WF, Chokroverty S AM J MANAG CARE 2000 6 11 Suppl S574-S579
38. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ BJU INT 2001 87 9 760-766
39. Prevalence and burden of overactive bladder in the United States. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ WORLD J UROL 2003 20 6 327-336
40. Overactive bladder significantly affects quality of life. Abrams P, Kelleher CJ, Kerr LA, Rogers RG AM J MANAG CARE 2000 6 11 Suppl S580-S590
41. Current and emerging investigational medical therapies for the treatment of overactive bladder. Tiwari A, Naruganahalli KS EXPERT OPIN INVEST DRUGS 2006 15 9 1017-1037
42. Recent advances in the management of the neurogenic bladder. Elliott DS, Boone TB UROLOGY 2000 56 6 Suppl 1 76-81
43. Defining overactive bladder: Epidemiology and burden of disease. Tubaro A UROLOGY 2004 64 6 Suppl 1 2-6
44. The overactive bladder and quality of life. Epstein LB, Goldberg RP INT J FERTIL WOMENS MED 2005 50 1 30-36
45. Estimated economic costs of overactive bladder in the United States. Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, Corey R, Zhou SZ, Hunt TL UROLOGY 2003 61 6 1123-1128
46. Health-related consequences of overactive bladder: An economic perspective. Hu TW, Wagner TH BJU INT 2005 96 Suppl 1 43-45
47. Behavioral vs drug treatment for urge urinary incontinence in older women: A randomized controlled trial. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, Candib D JAMA-J AM MED ASSOC 1998 280 23 1995-2000
48. Combined behavioral and drug therapy for urge incontinence in older women. Burgio KL, Locher JL, Goode PS J AM GERIATR SOC 2000 48 4 370-374
49. Identifying and treating urinary incontinence. The crucial role of the primary care physician. Knapp PM Jr POSTGRAD MED 1998 103 4 279-280
50. Hormonal treatment of male infertility: Promises and pitfalls. Madhukar D, Rajender S J ANDROL 2009 30 2 95-112
51. Towards more objectivity in diagnosis and management of male fertility. Comhaire FH, de Kretser DM, Farley TM, Rowe PJ INT J ANDROL 1987 7 Suppl 1-53
52. Sperm morphology, motility, and concentration in fertile and infertile men. Guzick DS, Overstreet JW, Factor-Litvak P, Brazil CK, Nakajima ST, Coutifaris C, Carson SA, Cisneros P, Steinkampf MP, Hill JA, Xu D et al N ENGL J MED 2001 345 19 1388-1393
53. The present and future state of hormonal treatment for male infertility. Liu PY, Handelsman DJ HUM REPROD UPDATE 2003 9 1 9-23
54. Contribution of environmental factors to the risk of male infertility. Oliva A, Spira A, Multigner L HUM REPROD 2001 16 8 1768-1776
55. Inflammatory mediators exert toxic effects of oxidative stress on human spermatozoa. Fraczek M, Kurpisz M J ANDROL 2007 28 2 325-333
56. Oxidative stress and male infertility - A clinical perspective. Tremellen K HUM REPROD UPDATE 2008 14 3 243-258
57. Expression of co-stimulatory molecules, chemokine receptors and proinflammatory cytokines in dendritic cells from normal and chronically inflamed rat testis. Rival C, Guazzone VA, von Wulffen W, Hackstein H, Schneider E, Lustig L, Meinhardt A, Fijak M MOL HUM REPROD 2007 13 12 853-861
58. Role of caspases in male infertility. Said TM, Paasch U, Glander HJ, Agarwal A HUM REPROD UPDATE 2004 10 1 39-51
59. Oxidative stress and male infertility: From research bench to clinical practice. Saleh RA, Agarwal A J ANDROL 2002 23 6 737-752
60. Proinflammatory cytokines as an intermediate factor enhancing lipid sperm membrane peroxidation in in vitro conditions. Fraczek M, Sanocka D, Kamieniczna M, Kurpisz M J ANDROL 2008 29 1 85-92
61. Male genital tract inflammation: The role of selected interleukins in regulation of pro-oxidant and antioxidant enzymatic substances in seminal plasma. Sanocka D, Jedrzejczak P, Szumala-Kaekol A, Fraczek M, Kurpisz M J ANDROL 2003 24 3 448-455
62. Relationship of seminal plasma interleukin (IL) -8 and IL-6 with semen quality. Eggert-Kruse W, Boit R, Rohr G, Aufenanger J, Hund M, Strowitzki T HUM REPROD 2001 16 3 517-528
63. Strategies for the infertile man. Oehninger S SEMIN REPROD MED 2001 19 3 231-237
64. US-07332482: Method for treating benign prostatic hyperplasia. Adorini L, Colli E US PATENT 2008 February 19
65. Human bladder as a novel target for vitamin D receptor ligands. Crescioli C, Morelli A, Adorini L, Ferruzzi P, Luconi M, Vannelli GB, Marini M, Gelmini S, Fibbi B, Donati S, Villari D et al J CLIN ENDOCRINOL METAB 2005 90 2 962-972
66. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-κB pathways. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M et al PROSTATE 2009 69 5 480-493
67. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Mancina R, Gelmini S, Serio M, Villari D, Vannelli GB, Colli E et al EUR J ENDOCRINOL 2004 150 4 591-603
68. BioXell: Product pipeline - Elocalcitol in male infertility. BioXell SpA COMPANY WORLD WIDE WEB SITE 2009 February 27
69. BioXell: Product pipeline - Elocalcitol in BPH. BioXell SpA COMPANY WORLD WIDE WEB SITE 2009 February 27
70. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Stoner E UROLOGY 1994 43 3 284-292
71. α-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y J UROL 1982 128 4 836-839
72. State of the art on the efficacy and tolerability of α-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Djavan B, Chapple C, Milani S, Marberger M UROLOGY 2004 64 6 1081-1088
73. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Latest update on α-adrenoceptor antagonists. Milani S, Djavan B BJU INT 2005 95 Suppl 4 29-36
74. Tamsulosin: An update of its role in the management of lower urinary tract symptoms. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ DRUGS 2002 62 1 135-167
75. Intraoperative floppy iris syndrome associated with tamsulosin. Chang DF, Campbell JR J CATARACT REFRACTIVE SURG 2005 31 4 664-673
76. Floppy iris syndrome associated with tamsulosin: What are the implications for urologists? Tiwari A NAT CLIN PRACT UROL 2005 2 12 594-595
77. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Lee M AM J HEALTH-SYSTEM PHARM 2003 60 14 1426-1439
78. Natural history of prostatism: Risk factors for acute urinary retention. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM J UROL 1997 158 2 481-487
79. Elocalcitol (BXL-628): A novel, investigational therapy for the therapeutic management of benign prostatic hyperplasia. Tiwari A EXPERT OPIN INVEST DRUGS 2008 17 5 819-824
80. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Gopal M, Haynes K, Bellamy SL, Arya LA OBSTET GYNECOL 2008 112 6 1311-1318
81. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED et al N ENGL J MED 2003 349 25 2387-2398
82. 3 analogue in a rat model of bladder outlet obstruction. Schröder A, Colli E, Maggi M, Andersson KE BJU INT 2006 98 3 637-642
83. Costs associated with the management of overactive bladder and related comorbidities. Darkow T, Fontes CL, Williamson TE PHARMACOTHERAPY 2005 25 4 511-519
84. BioXell reports financial results for 2008. BioXell SpA PRESS RELEASE 2009 April 08
85. BioXell reports top-line OAB phase IIb results. BioXell SpA PRESS RELEASE 2009 April 08
86. Male infertility may have obesity link: Researchers examine connection between body mass index and infertility. WebMD Health News INTERNET SITE 2006 September 01
87. The cost-effectiveness of treatments for male infertility. Movassaghi M, Turek PJ EXPERT REV PHARMACOECON OUTCOMES RES 2008 8 2 197-206
88. BioXell: Product pipeline - Elocalcitol in OAB. BioXell SpA COMPANY WORLD WIDE WEB SITE 2009 February 27
89. BXL628 in the treatment of BPH: A multicentre, randomized, placebo-controlled clinical trial. Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, Scarpa R, Usai E, Colli E EUR UROL SUPPL 2005 4 3 211
90. The current and future burden and cost of overactive bladder in five European countries. Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, Lloyd A EUR UROL 2006 50 5 1050-1057
91. Discontinuation rates high for anticholinergic drugs used for urinary symptoms in women. Medscape Today (WebMD) INTERNET SITE 2008 December 23
92. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, Steel M EUR UROL 2006 50 2 317-326
93. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K BMJ (CLINICAL RES ED) 2006 332 7539 755-759
94. PAK and other Rho-associated kinases - Effectors with surprisingly diverse mechanisms of regulation. Zhao ZS, Manser E BIOCHEM J 2005 386 Pt 2 201-214
95. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. AUA Practice Guidelines Committee J UROL 2003 170 2 Pt 1 530-547
96. α- and α2-adrenoceptors in BPH. Takeda M, Hatano A, Arai K, Obara K, Tsutsui T, Takahashi K EUR UROL 1999 36 Suppl 1 31-34
97. Cyclooxygenase-2 inhibitors and cardiovascular risk. Solomon SD CURR OPIN CARDIOL 2006 21 6 613-617
98. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Black L, Naslund MJ, Gilbert TD Jr, Davis EA, Ollendorf DA AM J MANAG CARE 2006 12 4 Suppl S099-S110
99. Long-term aspects of medical treatment of BPH. Schulman CC EUR UROL 2001 40 Suppl 3 8-12
100. BioXell announces restructuring following review of portfolio. BioXell SpA PRESS RELEASE 2009 April 28
101. Analyst Presentation. BioXell SpA COMPANY PRESENTATION 2009 April 30
102. Cellular signaling in the bladder. Baskin LS, Hayward SW, Sutherland RA, DiSandro MS, Thomson AA, Cunha GR FRONT BIOSCI 1997 2 d592-d595
103. The physiology of vitamin D: Current concepts. Kochupillai N. INDIAN J MED RES 2008 127 3 256-262
104. Vitamin D receptor modulators for inflammation and cancer. Yee YK, Chintalacharuvu SR, Lu J, Nagpal S MINI REV MED CHEM 2005 8 761-778
105. Vitamin D therapy. Geller JL, Adams JS CURR OSTEOPOROS REP 2008 6 1 5-11